Vestal Point Capital LP Has $71.59 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Vestal Point Capital LP grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 108.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 520,000 shares of the biotechnology company's stock after acquiring an additional 270,000 shares during the quarter. Ascendis Pharma A/S comprises 4.2% of Vestal Point Capital LP's holdings, making the stock its 4th largest position. Vestal Point Capital LP owned 0.86% of Ascendis Pharma A/S worth $71,588,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ASND. RA Capital Management L.P. raised its stake in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after buying an additional 114,167 shares during the period. Artisan Partners Limited Partnership raised its position in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after buying an additional 39,309 shares during the period. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the period. Finally, Capital International Investors raised its position in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after buying an additional 753,859 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ASND. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Royal Bank of Canada boosted their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, Wedbush upped their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Trading Up 1.2%

Shares of Ascendis Pharma A/S stock traded up $1.95 during trading on Friday, reaching $162.00. The company's stock had a trading volume of 212,034 shares, compared to its average volume of 486,735. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The firm has a market cap of $9.88 billion, a PE ratio of -22.82 and a beta of 0.41. The company has a 50-day moving average price of $157.41 and a two-hundred day moving average price of $143.59.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.